CA-125 AUC as a new prognostic factor for patients with ovarian cancer

Gynecologic Oncology

Volumn 97, Issue 2, 2005, Pages 529-534

  Mano, A ^a   Falcao A ^a   Godinho, I ^b   Santos, J ^b   Leitao F ^b   Oliveira, C ^b   Caramona, M ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

CA 125 kinetics; Ovarian cancer; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 18144378405     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.01.040     Document Type: Article

References (15)

1. V.B. Vicki Treatment options for ovarian cancer Clin. Obstet. Gynecol. 44 3 2001 522 530
2. E.P. Eduard, and N.B. Mack Epithelial ovarian cancer: prevention, diagnosis, and treatment CA Cancer J. Clin. 49 1999 297 320
3. R.C. Bast Jr., T.L. Klug, E. St. John, E. Jenison, J.M. Niloff, and H. Lazarus A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N. Engl. J. Med. 309 1983 883 887
4. R.C. Bast Jr., F.J. Xu, Y.H. Yu, S. Barnhill, Z. Zhang, and G.B. Mills CA 125: the past and the future Int. J. Biol. Markers 13 4 1998 179 187
5. P.H.M. Amin, B.K. Gunnar, K. Janne, P.B. Ole, M.A. Vera, and G.T. Claes Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis Obstet. Gynecol. 79 1992 1002 1010
6. B. Jean-Michel, T. François, A. Christine, C. Jacqueline, D. Alain, and J. Nelly Kinetic of serum marker concentrations and usefulness in clinical monitoring Clin. Chem. 45 10 1999 1695 1707
7. G. Angiolo, Z. Paolo, L. Fabio, M. Tiziano, S. Enrico, and B. Tiziana Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study Gynecol. Oncol. 58 1995 42 47
8. M.E.L. Van Der Burg, F.B. Lammes, W.L.J. Van Putten, and G. Stoter Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy Gynecol. Oncol. 30 1988 307 312
9. R.E. Hawkins, K. Roberts, E. Wiltshaw, J. Mundy, I.J. Fryatt, and V.R. McCready The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma Br. J. Obstet. Gynaecol. 96 1989 1395 1399
10. J.H. Verda, D. Lee, H. Michael, T.S. John, B. Andrew, L.C.P. Daniel, and R.C. Bast Jr. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received chemotherapy after surgical cytoreduction Am. J. Obstet. Gynecol. 163 1990 1164 1167
11. S. Čolaković, V. Lukiç, L. Mitroviç, S. Jeliç, S. Šušnjar, and J. Marinkoviç Prognostic value of CA 125 kinetics and half-life in advanced ovarian cancer Int. J. Biol. Markers 15 2 2000 147 152
12. P.M. Fayers, G. Rusting, R. Wood, A. Nelstrop, R.C.F. Leonard, and P. Wilkinson The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the medical research council working party on gynaecological cancer Int. J. Gynecol. Cancer 3 1993 285 292
13. H.H. Christine, and S.B. Jonathan Ovarian cancer: epidemiology, biology, and prognostic factors Semin. Surg. Oncol. 19 2000 3 10
14. E.B. Richard, L.B. Michael, D.B. Jeffrey, M. Alberto, and J.D.S. Philip CA 125 regression: a model for epithelial ovarian cancer response Am. J. Obstet. Gynecol. 165 1991 360 367
15. E.B. Richard, L.B. Michael, D.B. Jeffery, M. Alberto, and J.D.S. Philip Serum CA 125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival Gynecol. Oncol. 47 1992 87 92